TTX-564 is under clinical development by Trueline Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TTX-564’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trueline Therapeutics overview
Trueline Therapeutics, a subsidiary of Anji Pharmaceuticals Inc, is a biotechnology research company engaged in developing novel therapeutics for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of TTX-564’s drug-specific PTSR and LoA scores, buy the report here.